82 results
8-K
EX-99.1
IMNM
Immunome Inc
28 Mar 24
Immunome Reports Full-Year 2023 Financial Results and Provides Update on Recently Acquired Assets
4:04pm
, which does not include gross proceeds of $230 million from the February financing.
Research and development expenses for the year ended December 31 … , 2023 were $23.1 million. In-process research and development expenses for the year ended December 31 2023 were $80.8 million.
General and administrative
8-K
EX-10.1
IMNM
Immunome Inc
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
, actual reimbursement for research, Development or Commercialization activities performed or paid for by Company after the grant of a License … Information of BMS shall not be used by Company for any purpose other than for the discovery, research, Development or Commercialization (including
8-K
IMNM
Immunome Inc
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
for, and bear the cost of, conducting research and development and preparing all regulatory filings and related submissions with respect to the BMS
8-K
EX-1.1
yrqh4nv
14 Feb 24
Other Events
4:11pm
424B5
0fn5do gpivguc2qpuo
14 Feb 24
Prospectus supplement for primary offering
4:09pm
424B5
d0416yv
13 Feb 24
Prospectus supplement for primary offering
4:36pm
8-K
EX-99.1
hfueuv23iphxsofdpm
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.2
cjduwlc
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
k1dn8
13 Feb 24
Results of Operations and Financial Condition
4:10pm
S-3ASR
dc11wl
13 Feb 24
Automatic shelf registration
4:04pm
8-K
EX-2.1
cras9z4ewcze54sqk
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
8-K/A
EX-99.1
dkax6 hti
22 Nov 23
Report of Independent Auditors
4:02pm
8-K/A
EX-99.2
72ldugd
22 Nov 23
Report of Independent Auditors
4:02pm
8-K/A
EX-99.3
rnc7ick
22 Nov 23
Report of Independent Auditors
4:02pm
8-K
EX-99.1
zd3gdugx9 05rtzigoy7
9 Nov 23
Immunome Reports Third Quarter 2023 Financial Results
4:52pm
8-K
now 4w6wi485y7
4 Oct 23
Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies
6:56am
424B3
6caee6
28 Aug 23
Prospectus supplement
9:10am